JP2025503721A - がん治療用免疫刺激タンパク質をコードする組換えオルソポックスウイルスベクター - Google Patents

がん治療用免疫刺激タンパク質をコードする組換えオルソポックスウイルスベクター Download PDF

Info

Publication number
JP2025503721A
JP2025503721A JP2024542127A JP2024542127A JP2025503721A JP 2025503721 A JP2025503721 A JP 2025503721A JP 2024542127 A JP2024542127 A JP 2024542127A JP 2024542127 A JP2024542127 A JP 2024542127A JP 2025503721 A JP2025503721 A JP 2025503721A
Authority
JP
Japan
Prior art keywords
nucleic acid
viral
acid sequence
seq
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024542127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503721A5 (enExample
Inventor
コトゥグノ，ガブリエラ
スカルセッリ，エリサ
ダリーゼ，アンナ モレナ
ラーム，アルミン
レオニ，グイド
Original Assignee
ノイスコム アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノイスコム アーゲー filed Critical ノイスコム アーゲー
Publication of JP2025503721A publication Critical patent/JP2025503721A/ja
Publication of JP2025503721A5 publication Critical patent/JP2025503721A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024542127A 2022-01-17 2023-01-17 がん治療用免疫刺激タンパク質をコードする組換えオルソポックスウイルスベクター Pending JP2025503721A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22151830.1 2022-01-17
EP22151830 2022-01-17
PCT/EP2023/050917 WO2023135313A1 (en) 2022-01-17 2023-01-17 Recombinant orthopox viral vector encoding immunostimulatory proteins for cancer treatment

Publications (2)

Publication Number Publication Date
JP2025503721A true JP2025503721A (ja) 2025-02-04
JP2025503721A5 JP2025503721A5 (enExample) 2026-01-20

Family

ID=80222249

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024542127A Pending JP2025503721A (ja) 2022-01-17 2023-01-17 がん治療用免疫刺激タンパク質をコードする組換えオルソポックスウイルスベクター

Country Status (10)

Country Link
US (1) US20250115928A1 (enExample)
EP (1) EP4466286A1 (enExample)
JP (1) JP2025503721A (enExample)
KR (1) KR20240134204A (enExample)
CN (1) CN118556081A (enExample)
AU (1) AU2023207821A1 (enExample)
CA (1) CA3248326A1 (enExample)
IL (1) IL314357A (enExample)
MX (1) MX2024008847A (enExample)
WO (1) WO2023135313A1 (enExample)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2415783B1 (en) * 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
US8394385B2 (en) * 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
SG11202006457YA (en) * 2018-01-05 2020-08-28 Ottawa Hospital Res Inst Modified orthopoxvirus vectors
CN113454231A (zh) * 2018-12-21 2021-09-28 渥太华医院研究所 修饰的正痘病毒载体

Also Published As

Publication number Publication date
EP4466286A1 (en) 2024-11-27
AU2023207821A1 (en) 2024-09-05
MX2024008847A (es) 2024-07-25
KR20240134204A (ko) 2024-09-06
CA3248326A1 (en) 2023-07-20
CN118556081A (zh) 2024-08-27
IL314357A (en) 2024-09-01
WO2023135313A1 (en) 2023-07-20
US20250115928A1 (en) 2025-04-10

Similar Documents

Publication Publication Date Title
KR102351555B1 (ko) Hpv 및 관련 질환용 면역 증강 치료 백신
JP5710262B2 (ja) ポックスウイルス腫瘍細胞崩壊性ベクター
US20240132913A1 (en) Modified orthopoxvirus vectors
DK2212345T3 (en) Oncolytic poxvirus vectors
US20220056480A1 (en) Modified orthopoxvirus vectors
TW201623326A (zh) 白細胞介素１５蛋白質複合物及其用途
US12544433B2 (en) Melanoma canine vaccine compositions and methods of use thereof
KR20210005637A (ko) 종양 치료용 콕삭키바이러스 b
CN110845621A (zh) 一种靶向egfr和cd19双靶点的嵌合抗原受体方法
CN114657150A (zh) 用于改善免疫疗法的重组溶瘤腺病毒及其应用
JP2025522951A (ja) 腫瘍溶解性ワクシニアウイルスおよび組換えウイルスならびにその使用方法
CN106413726A (zh) 痘病毒溶瘤载体
US20250115928A1 (en) Recombinant Orthopox Viral Vector Encoding Immunostimulatory Proteins for Cancer Treatment
CN108440673A (zh) Fc融合蛋白PD1/FGFR1及其应用
TW202317172A (zh) Tnfsf-l融合蛋白及其用途
CN116769011B (zh) 一种视网膜母细胞瘤蛋白突变体及其制备方法和应用
CN115161293B (zh) 一种编码双特异性t细胞衔接子的溶瘤痘苗病毒及其制备方法和应用
HK40122972A (en) Nucleic acids encoding tgf-beta inhibitor and il-12 and uses thereof
WO2025068401A1 (en) Interleukin 15 variant
HK40114150A (en) Immunostimulatory mrna compositions and uses thereof
WO2024062098A1 (en) Recombinant pseudocowpox virus encoding an interleukin-12
JP2026509004A (ja) 腫瘍溶解性アデノウイルスベクターの新規投与レジメン
TW202430647A (zh) 編碼TGF-β抑制劑及IL-12之核酸及其用途
HK40031658A (en) Recombinant vaccinia virus and pharmaceutical composition comprising same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260109